Literature DB >> 8014451

Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C.

J Guéchot1, R E Poupon, P Giral, B Balkau, J Giboudeau, R Poupon.   

Abstract

The diagnostic values of aminoterminal propeptide of type III procollagen and hyaluronan serum levels were compared as markers of liver fibrosis in two chronic liver diseases of different etiologies and pathophysiologies, namely primary biliary cirrhosis and chronic viral hepatitis C. The results were analysed in terms of the histological extent of fibrosis. Both serum procollagen-III peptide and hyaluronan were elevated in patients with primary biliary cirrhosis and chronic viral hepatitis C (p < 0.0001) relative to control values. A positive correlation was found between serum procollagen-III peptide levels and the histological grade of fibrosis in primary biliary cirrhosis (p < 0.001) but not in chronic viral hepatitis C, while a strong correlation was found between serum hyaluronan levels and histological fibrosis in both primary biliary cirrhosis and chronic viral hepatitis C (p < 0.001), independent of age. These results suggest that, in chronic liver diseases, serum hyaluronan levels could be an important indicator of the extent of fibrosis and should be assayed to monitor the response to treatment in controlled clinical trials.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8014451     DOI: 10.1016/s0168-8278(94)80013-8

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  19 in total

1.  Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses.

Authors:  Nan Meng; Xiao Gao; Wei Yan; Mi Wang; Ping Liu; Xiao-Dan Lu; Shu-Juan Zhang; Ya-Qi Lu; Wang-Xian Tang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-04-16

2.  Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis.

Authors:  Anne-Charlotte de Gouville; Valerie Boullay; Gael Krysa; Julia Pilot; Jean-Marie Brusq; Florence Loriolle; Jean-Michel Gauthier; Stephen A Papworth; Alain Laroze; Françoise Gellibert; Stephane Huet
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

3.  Genetic variants of the IgA Fc receptor (FcalphaR, CD89) promoter in chronic hepatitis C patients.

Authors:  Azuma Watanabe; Toshibumi Shimokawa; Mitsuhiko Moriyama; Fumihiko Komine; Shuichi Amaki; Yasuyuki Arakawa; Chisei Ra
Journal:  Immunogenetics       Date:  2006-10-11       Impact factor: 2.846

4.  Correlation between stellate cell activation and serum fibrosis markers in choline-deficient L-amino acid-defined diet-induced rat liver fibrosis.

Authors:  K Hironaka; I Sakaida; K Uchida; K Okita
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

5.  Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease.

Authors:  Hiroshi Sakugawa; Tomofumi Nakayoshi; Kasen Kobashigawa; Tsuyoshi Yamashiro; Tatsuji Maeshiro; Satoru Miyagi; Joji Shiroma; Akiyo Toyama; Tomokuni Nakayoshi; Fukunori Kinjo; Atsushi Saito
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

6.  Comprehensive characterization of serum clinical chemistry parameters and the identification of urinary superoxide dismutase in a carbon tetrachloride-induced model of hepatic fibrosis in the female Hanover Wistar rat.

Authors:  Rosemary Smyth; Michael R Munday; Malcolm J York; Christopher J Clarke; Theo Dare; John A Turton
Journal:  Int J Exp Pathol       Date:  2007-10       Impact factor: 1.925

7.  Peroxiredoxin 2: a potential biomarker for early diagnosis of hepatitis B virus related liver fibrosis identified by proteomic analysis of the plasma.

Authors:  Ye Lu; Jie Liu; Chengzhao Lin; Haijian Wang; Ying Jiang; Jiyao Wang; Pengyuan Yang; Fuchu He
Journal:  BMC Gastroenterol       Date:  2010-10-13       Impact factor: 3.067

8.  Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage.

Authors:  Masato Yoneda; Hironori Mawatari; Koji Fujita; Kyoko Yonemitsu; Shingo Kato; Hirokazu Takahashi; Hiroyuki Kirikoshi; Masahiko Inamori; Yuichi Nozaki; Yasunobu Abe; Kensuke Kubota; Satoru Saito; Tomoyuki Iwasaki; Yasuo Terauchi; Shinji Togo; Shiro Maeyama; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2007-05-25       Impact factor: 7.527

9.  Current and emerging surrogate markers of hepatic fibrosis in primary biliary cirrhosis.

Authors:  Jayant A Talwalkar
Journal:  Liver Int       Date:  2008-07       Impact factor: 5.828

Review 10.  Hyaluronan as a therapeutic target in human diseases.

Authors:  Jiurong Liang; Dianhua Jiang; Paul W Noble
Journal:  Adv Drug Deliv Rev       Date:  2015-11-02       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.